Denali director plans $266K stock sale

Denali Therapeutics Inc. (DNLI) director Nancy Thornberry filed a notice of proposed sale under Rule 144 for 11,439 shares of common stock, with an indicated aggregate value of $266,128.34, to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.

Rhea-AI Filing Summary

Denali Therapeutics Inc. (DNLI) director Nancy Thornberry filed a notice of proposed sale under Rule 144 for 11,439 shares of common stock, with an indicated aggregate value of $266,128.34, to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.

The shares were acquired from the issuer upon vesting of restricted stock units during the period from January 8, 2024 through May 31, 2025.

Key Figures

Shares to be sold: 11,439 shares Aggregate value of shares: $266,128.34 Acquisition start date: January 8, 2024 +2 more

5 metrics

Shares to be sold 11,439 shares Common stock covered by Rule 144 notice for Denali Therapeutics Inc.

Aggregate value of shares $266,128.34 Value listed for the 11,439 DNLI shares proposed to be sold

Acquisition start date January 8, 2024 Start of period when RSUs vested and were acquired from issuer

Acquisition end date May 31, 2025 End of period when RSUs vested and were acquired from issuer

Notice date September 2, 2026 Date of the Rule 144 notice of proposed sale

Key Terms

Rule 144, Restricted Stock Units, aggregate value, NASDAQ

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Units financial

"Common | 01/08/2024 | Restricted Stock Units | Issuer"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

aggregate value financial

"Common | Morgan Stanley Smith Barney LLC Executive Financial Services ... | 266128.34"

NASDAQ market

"09/02/2026 | NASDAQ"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

FAQ

What does the Form 144 filing disclose for DNLI?

It discloses that director Nancy Thornberry plans to sell 11,439 shares of Denali Therapeutics Inc. common stock under Rule 144, with an indicated aggregate value of $266,128.34, through Morgan Stanley Smith Barney LLC on NASDAQ.

How many DNLI shares are covered by Nancy Thornberry’s planned Rule 144 sale?

The notice covers 11,439 shares of Denali Therapeutics Inc. common stock, proposed to be sold in a Rule 144 transaction through Morgan Stanley Smith Barney LLC on NASDAQ.

What is the approximate value of the DNLI shares in this Form 144?

The filing lists an aggregate value of $266,128.34 for the 11,439 DNLI shares proposed to be sold under Rule 144.

How were the DNLI shares in Nancy Thornberry’s Form 144 acquired?

The shares were acquired from Denali Therapeutics Inc. upon the vesting of restricted stock units during the period from January 8, 2024 through May 31, 2025.

When was the Form 144 notice for DNLI filed?

The notice of proposed sale under Rule 144 for Denali Therapeutics Inc. shares is dated September 2, 2026.

On which market is the DNLI stock in this Rule 144 filing to be sold?

The filing states that the 11,439 DNLI shares covered by the Rule 144 notice are to be sold on NASDAQ through Morgan Stanley Smith Barney LLC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:31 PM Accepted by SEC EDGAR 09/02/2026 - 04:31 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001797826
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Denali Therapeutics Inc.
SEC File Number	001-38311
Address of Issuer	161 Oyster Point Blvd. South San Francisco CALIFORNIA 94080
Phone	(650)866-8547
Name of Person for Whose Account the Securities are To Be Sold	NANCY THORNBERRY
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	11439	266128.34	159847403	09/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/08/2024	Restricted Stock Units	Issuer			11439	01/08/2024	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The securities to be sold were acquired upon the vesting of restricted stock units during the period of 01/08/2024 through 05/31/2025.
Date of Notice	09/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/03/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Nancy Thornberry
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)